Danwang Medical Technology Shanghai Co.
Latest round
- Series A
Last raised
- Sep 2021
Total raised
- $19M
Investors
- 5
About Danwang Medical Technology Shanghai Co.
Established in 2019 and based in Shanghai, China, D1med operates an organoid technology developer that focuses on tumor diagnosis and treatment field. It cooperates with Merck China, Fudan University, Shanghai Jiao Tong University, and Shanghai Pulmonary Hospital. The founder, Guoqiang Guoqiang graduated from Fudan University and has published his research work in Cell Stem Cell and CancerResearch. The company's business can be categorized into tumor personalized precision therapy, drug company R&D services, Patient in the Lab organ-like disease model library, and IVD reagents and automation equipment. It has also developed organoid service platforms for new drug research and development companies, such as Next Generation Diagnostics of Organoid, Next Generation Drug Diagnostics Platform of Organoid, and Next Generation Culture of Organoid., Ltd. generates revenue by clinical development and application of organoid technology.
Who invested in Danwang Medical Technology Shanghai Co.
5 investors across 2 rounds
See all investors in Danwang Medical Technology Shanghai Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Danwang Medical Technology Shanghai Co.
Who invested in Danwang Medical Technology Shanghai Co.?
Danwang Medical Technology Shanghai Co. has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Danwang Medical Technology Shanghai Co. raised?
Danwang Medical Technology Shanghai Co. has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Danwang Medical Technology Shanghai Co. last raise money?
Danwang Medical Technology Shanghai Co.'s most recent round on record is a Series A, in Sep 2021.
What does Danwang Medical Technology Shanghai Co. do?
Established in 2019 and based in Shanghai, China, D1med operates an organoid technology developer that focuses on tumor diagnosis and treatment field.
Where is Danwang Medical Technology Shanghai Co. headquartered?
Danwang Medical Technology Shanghai Co. is headquartered in Hangzhou, China.
Which VCs invest in companies like Danwang Medical Technology Shanghai Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, Taibao Capital and Hengxu Capital back healthcare companies at Danwang Medical Technology Shanghai Co.'s stage. Their profiles are linked below.
VCs backing healthcare startups at Series A
Raising like Danwang Medical Technology Shanghai Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.